{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:40:42Z","timestamp":1792521642520,"version":"4.5.0"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Monoclonal antibodies (mAbs) have become attractive tools for both the treatment and prevention of influenza A viruses due to their ability to target several viral components, which confers broad therapeutic potential. Advances in biotechnology, such as hybridoma technology, phage display technology, B cell immortalization, and artificial intelligence (Al)-driven antibody design, have significantly accelerated the development of effective mAbs. Clinical trials have shown that mAbs can improve clinical outcomes particularly in high-risk and immunocompromised populations by lowering viral loads and reducing disease severity. However, high production costs, the need for intravenous administration, and the risk of viral escape mutations are some of the obstacles to widespread clinical adoption. Post-marketing surveillance serves as a valuable source of information regarding safety, real-world effectiveness, and patterns of resistance. Broadly neutralizing antibodies (bnAbs), particularly those directed against conserved regions of the virus\u2019s surface proteins, such as hemagglutinin (HA) and neuraminidase (NA), have demonstrated efficacy against antigenic drift-derived variants. Nevertheless, the emergence of escape mutants underscores the need for careful monitoring of mAb candidates and combination therapy. Monitoring genomic shifts requires a careful focus on the targeted regions affected by combination therapy. Challenges in accessibility are compounded by financial barriers, emphasizing the importance of large-scale production and alternative delivery methods, such as inhaled mAbs. To ensure that future mAb-based therapies for influenza A are both effective and accessible, it is critical to integrate resistance surveillance tools, monitoring AI, and advanced computational modeling in therapeutic strategies. This comprehensive review discusses the potential of mAbs to enhance influenza A treatment by offering precise and adaptable alternatives to traditional antivirals. It also examines recent technological advances, clinical performance, and scalability that may redefine future therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fmicb.2025.1738181","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:20:39Z","timestamp":1768206039000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["RETRACTED: Broadly neutralizing monoclonal antibodies against influenza A viruses: current insights and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Nahed N.","family":"Mahrous","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, College of Science, University of Hafr Al-Batin","place":["Hafr Al-Batin, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohoud S.","family":"Alhumaidan","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz S.","family":"Alkhoshaiban","sequence":"additional","affiliation":[{"name":"Unit of Scientific Research, Applied College, Qassim University","place":["Qassim, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan T.","family":"Tafish","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, SMC Hospital","place":["Riyadh, Saudi Arabia"]},{"name":"College of Pharmacy, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah F.","family":"Al-Ghnnam","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunity, Research Centre, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Althubyani","sequence":"additional","affiliation":[{"name":"Comparative Medicine Department, Research Centre, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Al-Hubaysh","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Science, Prince Nourah bint Abdulrahman University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya F.","family":"Jamous","sequence":"additional","affiliation":[{"name":"Wellness and Preventative Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST)","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref1","volume-title":"Meyler\u2019s side effects of drugs: The international encyclopedia of adverse drug reactions and interactions","author":"Aronson","year":"2015"},{"key":"ref2","first-page":"199","article-title":"Amantadine and Rimantadine","volume-title":"Meyler's side effects of drugs","author":"Aronson","year":"2016"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e01696","DOI":"10.1128\/JVI.01696-18","article-title":"Broadly cross-reactive, nonneutralizing antibodies against influenza B virus hemagglutinin demonstrate effector function-dependent protection against lethal viral challenge in mice","volume":"93","author":"Asthagiri Arunkumar","year":"2019","journal-title":"J. Virol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2023.06.005","article-title":"Accelerating antibody discovery and design with artificial intelligence: recent advances and prospects","volume":"95","author":"Bai","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1049134","DOI":"10.3389\/fviro.2022.1049134","article-title":"The influenza hemagglutinin stem antibody CR9114: evidence for a narrow evolutionary path towards universal protection","volume":"2","author":"Beukenhorst","year":"2022","journal-title":"Front. Virol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e01027","DOI":"10.1128\/JVI.01027-20","article-title":"Matrix protein 2 extracellular domain-specific monoclonal antibodies are an effective and potentially universal treatment for influenza a","volume":"95","author":"Bimler","year":"2021","journal-title":"J. Virol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e80034","DOI":"10.1371\/journal.pone.0080034","article-title":"Mechanisms of hemagglutinin targeted influenza virus neutralization","volume":"8","author":"Brandenburg","year":"2013","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3390\/ijms18071541","article-title":"The interplay between the host receptor and influenza virus hemagglutinin and neuraminidase","volume":"18","author":"Byrd-Leotis","year":"2017","journal-title":"IJMS"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e38126","DOI":"10.1371\/journal.pone.0038126","article-title":"The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus","volume":"7","author":"Cao","year":"2012","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.7326\/0003-4819-156-7-201204030-00403","article-title":"Accuracy of rapid influenza diagnostic tests: a Meta-analysis","volume":"156","author":"Chartrand","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","article-title":"Principles and therapeutic applications of adaptive immunity","volume":"187","author":"Chi","year":"2024","journal-title":"Cell"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/antib12030046","article-title":"Expanding the reach of monoclonal antibodies: a review of synthetic nucleic acid delivery in immunotherapy","volume":"12","author":"Chung","year":"2023","journal-title":"Antibodies"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e28001","DOI":"10.1371\/journal.pone.0028001","article-title":"A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes","volume":"6","author":"Clementi","year":"2011","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza a hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40011-011-0009-6","article-title":"Influenza virus: a brief overview","volume":"82","author":"Dangi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"eabe5449","DOI":"10.1126\/scitranslmed.abe5449","article-title":"Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates","volume":"13","author":"Darricarr\u00e8re","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous Administration of Monoclonal Antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e34415","DOI":"10.1371\/journal.pone.0034415","article-title":"A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses","volume":"7","author":"De Marco","year":"2012","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.coviro.2012.02.005","article-title":"Broadly neutralizing antibodies against influenza virus and prospects for universal therapies","volume":"2","author":"Ekiert","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/rmv.370","article-title":"Molecular diagnosis of influenza","volume":"12","author":"Ellis","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e9106","DOI":"10.1371\/journal.pone.0009106","article-title":"New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets","volume":"5","author":"Friesen","year":"2010","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/v12030276","article-title":"Influenza a virus antibodies with antibody-dependent cellular cytotoxicity function","volume":"12","author":"Gao","year":"2020","journal-title":"Viruses"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1006\/viro.2000.0756","article-title":"Inhibition of interferon-mediated antiviral responses by influenza a viruses and other negative-Strand RNA viruses","volume":"279","author":"Garc\u00eda-Sastre","year":"2001","journal-title":"Virology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1126\/science.aam9321","article-title":"Nucleic acid detection with CRISPR-Cas13a\/C2c2","volume":"356","author":"Gootenberg","year":"2017","journal-title":"Science"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"12658","DOI":"10.1073\/pnas.0911806107","article-title":"Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza a viruses","volume":"107","author":"Grandea","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"Gubareva","year":"2000","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/19420862.2016.1167294","article-title":"Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza a virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza a","volume":"8","author":"Gupta","year":"2016","journal-title":"MAbs"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","article-title":"From original antigenic sin to the universal influenza virus vaccine","volume":"39","author":"Henry","year":"2018","journal-title":"Trends Immunol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza a infection: results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e46938","DOI":"10.2196\/46938","article-title":"The impact of point-of-care testing for influenza on antimicrobial stewardship (PIAMS) in UK primary care: protocol for a mixed methods study","volume":"12","author":"Hoang","year":"2023","journal-title":"JMIR Res. Protoc."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1128\/JVI.06665-11","article-title":"A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses","volume":"86","author":"Hu","year":"2012","journal-title":"J. Virol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nri3665","article-title":"Innate immunity to influenza virus infection","volume":"14","author":"Iwasaki","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-2334-10-71","article-title":"Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons","volume":"10","author":"Jackson","year":"2010","journal-title":"BMC Infect. Dis."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1002\/jmv.26990","article-title":"A brief review of influenza virus infection","volume":"93","author":"Javanian","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fimmu.2020.00767","article-title":"Target the host, kill the bug; targeting host respiratory immunosuppressive responses as a novel strategy to improve bacterial clearance during lung infection","volume":"11","author":"Kelly","year":"2020","journal-title":"Front. Immunol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/bioengineering11020185","article-title":"Leveraging artificial intelligence to expedite antibody design and enhance antibody\u2013antigen interactions","volume":"11","author":"Kim","year":"2024","journal-title":"Bioengineering"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1089\/vim.2017.0141","article-title":"Influenza virus: dealing with a drifting and shifting pathogen","volume":"31","author":"Kim","year":"2018","journal-title":"Viral Immunol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Resp Viruses"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza a virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","article-title":"Influenza virus hemagglutinin stalk-based antibodies and vaccines","volume":"3","author":"Krammer","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e00352","DOI":"10.1128\/AAC.00352-20","article-title":"A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza a virus infection","volume":"64","author":"Lim","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"199402","DOI":"10.1016\/j.virusres.2024.199402","article-title":"Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus","volume":"345","author":"Lin","year":"2024","journal-title":"Virus Res."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-540-75855-6_12","article-title":"History of influenza pandemics","volume-title":"Paleomicrobiology","author":"Lina","year":"2008"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1128\/CMR.00037-07","article-title":"Detection of respiratory viruses by molecular methods","volume":"21","author":"Mahony","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e0003418","DOI":"10.1371\/journal.pgph.0003418","article-title":"Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries","volume":"4","author":"Malhotra","year":"2024","journal-title":"PLOS Glob Public Health"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/v17050694","article-title":"Pathogenesis induced by influenza virus infection: role of the early events of the infection and the innate immune response","volume":"17","author":"M\u00e1rquez-Bandala","year":"2025","journal-title":"Viruses"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e01144-21","DOI":"10.1128\/mBio.01144-21","article-title":"A prevalent focused human antibody response to the influenza virus hemagglutinin head interface","volume":"12","author":"McCarthy","year":"2021","journal-title":"MBio"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrmicro3231","article-title":"The co-pathogenesis of influenza viruses with bacteria in the lung","volume":"12","author":"McCullers","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1517\/14656566.2015.1066336","article-title":"Peramivir: an intravenous neuraminidase inhibitor","volume":"16","author":"Mclaughlin","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1345\/1542-6270(2001)035<>2.0.CO;2","article-title":"Neuraminidase inhibitors: zanamivir and oseltamivir","volume":"35","author":"McNicholl","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43141-021-00143-1","article-title":"Hybridoma technology; advancements, clinical significance, and future aspects","volume":"19","author":"Mitra","year":"2021","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.immuni.2022.10.015","article-title":"Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza a viruses","volume":"55","author":"Moin","year":"2022","journal-title":"Immunity"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase Inhibitors for Influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"e22837","DOI":"10.1002\/jbt.22837","article-title":"Cost-effective strategies for the production of monoclonal antibodies","volume":"35","author":"M\u00fcller","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ni.3684","article-title":"Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins","volume":"18","author":"Nachbagauer","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref59","first-page":"241","article-title":"Production of complex proteins in plants: from farming to manufacturing","volume-title":"Biopharmaceutical manufacturing, cell engineering","author":"Nausch","year":"2024"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.virol.2009.03.026","article-title":"The origin and global emergence of adamantane resistant a\/H3N2 influenza viruses","volume":"388","author":"Nelson","year":"2009","journal-title":"Virology"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e10152","DOI":"10.1371\/journal.pone.0010152","article-title":"Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice","volume":"5","author":"Nguyen","year":"2010","journal-title":"PLoS One"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-981-97-6270-5_3","article-title":"The basics of large-scale commercial production of monoclonal antibodies","volume-title":"Industrial microbiology and biotechnology","author":"Nikita","year":"2024"},{"key":"ref63","article-title":"Practical challenges of point-of-care testing","volume-title":"Clinical virology manual","author":"Ortiz","year":"2023"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1055\/s-0041-1733830","article-title":"Antiviral treatments for influenza","volume":"42","author":"Palomba","year":"2021","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41591-020-0937-x","article-title":"Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model","volume":"26","author":"Park","year":"2020","journal-title":"Nat. Med."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1039\/D4AY00508B","article-title":"An overview of influenza a virus detection methods: from state-of-the-art of laboratories to point-of-care strategies","volume":"16","author":"Peng","year":"2024","journal-title":"Anal. Methods"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e71393","DOI":"10.7554\/eLife.71393","article-title":"Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies","volume":"10","author":"Phillips","year":"2021","journal-title":"eLife"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1074\/jbc.R500020200","article-title":"The M2 proton channels of influenza a and B viruses","volume":"281","author":"Pinto","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"e01273","DOI":"10.1128\/aac.01273-23","article-title":"A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza a illness","volume":"68","author":"Plotnik","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1128\/JVI.02165-08","article-title":"Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza a virus H5N1 infection","volume":"83","author":"Prabhu","year":"2009","journal-title":"J. Virol."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e1764","DOI":"10.1002\/cnr2.1764","article-title":"Technological advancements in cancer diagnostics: improvements and limitations","volume":"6","author":"Pulumati","year":"2023","journal-title":"Cancer Rep. (Hoboken, N. J.)"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3389\/fphar.2018.01079","article-title":"Quality, non-clinical and clinical considerations for biosimilar monoclonal antibody development: EU, WHO, USA, Canada, and BRICS-TM regulatory guidelines","volume":"9","author":"Rahalkar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/infdis\/jiu539","article-title":"Efficacy and safety of treatment with an anti-M2e monoclonal antibody in experimental human influenza","volume":"211","author":"Ramos","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1080\/10826068.2014.985834","article-title":"Continuous processing for production of biopharmaceuticals","volume":"45","author":"Rathore","year":"2015","journal-title":"Prep. Biochem. Biotechnol."},{"key":"ref75","first-page":"2915","article-title":"AI-based antibody design targeting recent H5N1 avian influenza strains","volume-title":"Comput. Struct. Biotechnol. J.","author":"Santolla","year":"2025"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13073-018-0543-4","article-title":"Pathogen detection in the CRISPR\u2013Cas era","volume":"10","author":"Sashital","year":"2018","journal-title":"Genome Med."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"104562","DOI":"10.1016\/j.antiviral.2019.104562","article-title":"New antibody-based prevention and treatment options for influenza","volume":"170","author":"Sedeyn","year":"2019","journal-title":"Antivir. Res."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.virol.2011.06.021","article-title":"A novel monoclonal antibody effective against lethal challenge with swine-lineage and 2009 pandemic H1N1 influenza viruses in mice","volume":"417","author":"Shao","year":"2011","journal-title":"Virology"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.3978\/j.issn.2072-1439.2013.06.14","article-title":"Novel hemagglutinin-based influenza virus inhibitors","volume":"5","author":"Shen","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4049\/immunohorizons.2300102","article-title":"Recent advances in the development of monoclonal antibodies and next-generation antibodies","volume":"7","author":"Singh","year":"2023","journal-title":"ImmunoHorizons"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","article-title":"Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin","volume":"69","author":"Skehel","year":"2000","journal-title":"Annu. Rev. Biochem."},{"key":"ref82","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0140-6736(00)78541-2","article-title":"A virus obtained from influenza patients","volume":"222","author":"Smith","year":"1933","journal-title":"Lancet"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.tibtech.2013.10.002","article-title":"Microbials for the production of monoclonal antibodies and antibody fragments","volume":"32","author":"Spadiut","year":"2014","journal-title":"Trends Biotechnol."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/antib14010004","article-title":"How broadly Neutralising antibodies are redefining immunity to influenza","volume":"14","author":"Steventon","year":"2025","journal-title":"Antibodies (Basel)"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3389\/fimmu.2022.944907","article-title":"Monoclonal antibodies targeting the influenza virus N6 neuraminidase","volume":"13","author":"Strohmeier","year":"2022","journal-title":"Front. Immunol."},{"key":"ref87","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.279.5349.393","article-title":"Characterization of an avian influenza a (H5N1) virus isolated from a child with a fatal respiratory illness","volume":"279","author":"Subbarao","year":"1998","journal-title":"Science"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza a viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/v12091033","article-title":"Progress in the development of universal influenza vaccines","volume":"12","author":"Sun","year":"2020","journal-title":"Viruses"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1506849","DOI":"10.3389\/fonc.2024.1506849","article-title":"Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight","volume":"14","author":"Sun","year":"2024","journal-title":"Front. Oncol."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7883\/yoken.JJID.2005.195","article-title":"Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines","volume":"58","author":"Tamura","year":"2005","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1128\/JVI.00469-12","article-title":"A Pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-Spectrum EfficacyIn vivo","volume":"86","author":"Tan","year":"2012","journal-title":"J. Virol."},{"key":"ref93","doi-asserted-by":"publisher","first-page":"13580","DOI":"10.1128\/JVI.02289-14","article-title":"Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza a virus hemagglutinin","volume":"88","author":"Tan","year":"2014","journal-title":"J. Virol."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.chom.2010.05.009","article-title":"Influenza virus evolution, host adaptation, and pandemic formation","volume":"7","author":"Taubenberger","year":"2010","journal-title":"Cell Host Microbe"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"10890","DOI":"10.1073\/pnas.1502374112","article-title":"A broadly neutralizing human monoclonal antibody is effective against H7N9","volume":"112","author":"Tharakaraman","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PLoS One"},{"key":"ref97","first-page":"2024","article-title":"Antiviral mechanisms and preclinical evaluation of amantadine analogs that continue to inhibit influenza a viruses with M2 S31N-based drug resistance","author":"Tietjen","year":"2024","journal-title":"bioRxiv"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.ymthe.2024.05.036","article-title":"In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection","volume":"32","author":"Tkaczyk","year":"2024","journal-title":"Mol. Ther."},{"key":"ref99","first-page":"576","article-title":"Influenza viruses. In Diseases of Swine","author":"Van Reeth","year":"2019"},{"key":"ref100","first-page":"93","article-title":"Antibody-dependent cellular cytotoxicity in influenza virus infection","volume-title":"Curr. Top. Microbiol. Immunol.","author":"Vanderven","year":"2017"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"152279","DOI":"10.1016\/j.imbio.2022.152279","article-title":"Innate and adaptive immune responses against influenza a virus: immune evasion and vaccination strategies","volume":"227","author":"Varghese","year":"2022","journal-title":"Immunobiology"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.virusres.2014.03.015","article-title":"Molecular mechanisms enhancing the proteome of influenza a viruses: an overview of recently discovered proteins","volume":"185","author":"Vasin","year":"2014","journal-title":"Virus Res."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"e00052","DOI":"10.1128\/JVI.00052-20","article-title":"Airway delivery of anti-influenza monoclonal antibodies results in enhanced antiviral activities and enables broad-coverage combination therapies","volume":"94","author":"Vigil","year":"2020","journal-title":"J. Virol."},{"key":"ref104","first-page":"1046","article-title":"Clinical pharmacology of antiinfective drugs","volume-title":"Remington and Klein\u2019s infectious diseases of the fetus and newborn infant","author":"Wade","year":"2025"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/S0140-6736(12)61690-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Wang","year":"2012","journal-title":"Lancet"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1128\/CDLI.12.3.367-370.2005","article-title":"Evaluation of three immunoassay kits for rapid detection of influenza virus a and B","volume":"12","author":"Weinberg","year":"2005","journal-title":"Clin. Vaccine Immunol."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.bi.56.070187.002053","article-title":"The structure and function of the hemagglutinin membrane glycoprotein of influenza virus","volume":"56","author":"Wiley","year":"1987","journal-title":"Annu. Rev. Biochem."},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41564-017-0011-8","article-title":"Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes","volume":"2","author":"Wohlbold","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref109","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref110","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41594-018-0025-9","article-title":"Structural insights into the design of novel anti-influenza therapies","volume":"25","author":"Wu","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref1101","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/82_2014_396","article-title":"Evolution and ecology of influenza A viruses","volume":"385","author":"Yoon","year":"2014","journal-title":"CTMI"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"11509","DOI":"10.1073\/pnas.172199599","article-title":"Influenza a virus nucleoprotein is a major target antigen for cross-reactive anti\u2013influenza a virus cytotoxic T lymphocytes","volume":"99","author":"Yewdell","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1134\/S1021443724607766","article-title":"Recombinant monoclonal antibodies synthesized in plant expression systems: problems and prospects","volume":"71","author":"Zagorskaya","year":"2024","journal-title":"Russ. J. Plant Physiol."},{"key":"ref113","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jmoldx.2024.04.004","article-title":"CRISPR-based assays for point-of-need detection and subtyping of influenza","volume":"26","author":"Zhang","year":"2024","journal-title":"J. Molecular Diagnostics: JMD"}],"updated-by":[{"DOI":"10.3389\/fmicb.2026.2026341","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000}}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1738181\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:11:16Z","timestamp":1792519876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1738181\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":114,"alternative-id":["10.3389\/fmicb.2025.1738181"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1738181","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1738181"}}